Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

132.97 +1.64 (+1.25%)
Streaming Delayed Price Updated: 3:02 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
News headline image
Gilead Sciences's Q1 2026 Earnings: What to Expect
Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth. 
Via Barchart.com
Topics ETFs Workforce
News headline image
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution
In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines... 
Via MarketMinute
News headline image
Options Action: Naked Put Trade Ideas for March 31
With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener. 
Via Barchart.com
GILEAD SCIENCES INC (NASDAQ:GILD): A Durable Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗
This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition ↗
Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms. 
Via Benzinga
News headline image
The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips
As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
3 Reasons to Avoid GILD and 1 Stock to Buy Instead
Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead ... 
Via StockStory
Topics Stocks
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
Movers and shakers in today's after-hours session for S&P500 stocks? ↗
Via Chartmill
News headline image
2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights. 
Via Barchart.com
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
2 Recession-Resistant Dividend Stocks to Buy Now ↗
It's important to always be prepared. 
Via The Motley Fool
Topics Economy
News headline image
What 16 Analyst Ratings Have To Say About Gilead Sciences ↗
 
Via Benzinga
News headline image
3 Blue-Chip Stocks Built for a Rotating Market ↗
Via MarketBeat
News headline image
These 3 Cash Flow Machines Provide Stability in Uncertain Markets ↗
Via MarketBeat
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
Compugen (CGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗
Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗
Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
P/E Ratio Insights for Gilead Sciences ↗
 
Via Benzinga
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
Kymera (KYMR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir... 
Via MarketMinute
Topics Intellectual Property
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Arcus (RCUS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.